Metabolomics in patients with psychosis: A systematic review. Issue 6 (4th August 2018)

• Record Type: Journal Article
• Authors: Li, Christopher; Wang, Aviva; Wang, Chloe; Ramamurthy, Janani; Zhang, Edlyn; Guadagno, Elena; Trakadis, Yannis
• Is Part Of: American journal of medical genetics. Volume 177:Issue 6(2018)
• Page Start: 580
• Page End: 588
• Publication Date: 2018-08-04
• Subjects: biomarkers -- bipolar disorder -- pathophysiology -- schizophrenia; Neuropsychiatry -- Periodicals; Medical genetics -- Periodicals; 616.8904205
• DOI: 10.1002/ajmg.b.32662
• Languages: English
• ISSNs: 1552-4841

Abstract

Abstract : The purpose of this article is to provide a comprehensive review of metabolomics studies for psychosis, as a means of biomarker discovery. Manuscripts were selected for review if they involved discovery of metabolites using high‐throughput analysis in human subjects and were published in the last decade. The metabolites identified were searched in Human Metabolome Data Base (HMDB) for a link to psychosis. Metabolites associated with psychosis based on evidence in HMBD were then searched using PubMed to explore the availability of further evidence. Almost all of the studies which underwent full review involved patients with schizophrenia. Ten biomarkers were identified. Six of them were reported in two or more independent metabolomics studies: N‐acetyl aspartate, lactate, tryptophan, kynurenine, glutamate, and creatine . Four additional metabolites were encountered in a single metabolomics study but had significant evidence (two supporting articles or more) for a link to psychosis based on PubMed: linoleic acid, D‐serine, glutathione, and 3‐hydroxybutyrate . The pathways affected are discussed as they may be relevant to the pathophysiology of psychosis, and specifically of schizophrenia, as well as, constitute new drug targets for treatment of related conditions. Based on the biomarkers identified, early diagnosis of schizophrenia and/or monitoring may be possible.